370 related articles for article (PubMed ID: 34117129)
21. COVID-19 vaccines and kidney disease.
Windpessl M; Bruchfeld A; Anders HJ; Kramer H; Waldman M; Renia L; Ng LFP; Xing Z; Kronbichler A
Nat Rev Nephrol; 2021 May; 17(5):291-293. PubMed ID: 33558753
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Cusi MG
N Engl J Med; 2021 Jul; 385(1):90-92. PubMed ID: 33852796
[No Abstract] [Full Text] [Related]
23. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
24. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
[No Abstract] [Full Text] [Related]
25. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 vaccination: the VOICE for patients with cancer.
van der Veldt AAM; Oosting SF; Dingemans AC; Fehrmann RSN; GeurtsvanKessel C; Jalving M; Rimmelzwaan GF; Kvistborg P; Blank CU; Smit EF; Lemmens VEEP; Hiltermann TJN; Koopmans MPG; Huckriede ALW; Rots NY; van Els CACM; van Baarle D; Haanen JBAG; de Vries EGE
Nat Med; 2021 Apr; 27(4):568-569. PubMed ID: 33589821
[No Abstract] [Full Text] [Related]
27. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
28. Antibody responses to COVID-19 vaccines in older adults.
Bag Soytas R; Cengiz M; Islamoglu MS; Borku Uysal B; Yavuzer S; Yavuzer H
J Med Virol; 2022 Apr; 94(4):1650-1654. PubMed ID: 34921432
[TBL] [Abstract][Full Text] [Related]
29. Audio Interview: Antibody Responses to Natural Infection and Vaccination.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Apr; 384(14):e65. PubMed ID: 33826826
[No Abstract] [Full Text] [Related]
30. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.
Eliakim-Raz N; Leibovici-Weisman Y; Stemmer A; Ness A; Awwad M; Ghantous N; Stemmer SM
JAMA; 2021 Dec; 326(21):2203-2204. PubMed ID: 34739043
[TBL] [Abstract][Full Text] [Related]
31. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy.
Mithal LB; Otero S; Shanes ED; Goldstein JA; Miller ES
Am J Obstet Gynecol; 2021 Aug; 225(2):192-194. PubMed ID: 33812808
[No Abstract] [Full Text] [Related]
32. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
33. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
34. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
35. Persistent Immunogenicity of the mRNA COVID-19 Vaccine in Patients Vaccinated Before Kidney Transplant.
Yi SG; Eagar T; Moore L; Huang HJ; Ibrahim H; Hobeika MJ; McMillan R; Podder H; Ghobrial RM; Gaber AO; Knight RJ
Transplantation; 2021 Oct; 105(10):e133-e134. PubMed ID: 34155187
[No Abstract] [Full Text] [Related]
36. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
37. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
38. Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.
Joob B; Wiwanitkit V
Clin Appl Thromb Hemost; 2021; 27():10760296211020833. PubMed ID: 34142570
[No Abstract] [Full Text] [Related]
39. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
40. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
Kozak KE; Ouyang L; Derkach A; Sherman A; McCall SJ; Famulare C; Chervin J; Daley RJ; Morjaria S; Mauro MJ; Rampal RK
Leukemia; 2021 Dec; 35(12):3578-3580. PubMed ID: 34741117
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]